Abstract
Meprin α is a zinc metalloproteinase (metzincin) that has been implicated in multiple dis-eases, including fibrosis and cancers. It has proven difficult to find small molecules that are capable of selectively inhibiting meprin α, or its close relative meprin β, over numerous other metzincins which, if inhibited, would elicit unwanted effects. We recently identified possible molecular starting points for meprin α-specific inhibition through an HTS effort (see part I, preceding paper). Here, in part II, we report further efforts to optimize potency and selectivity. We hope that a hydroxamic acid meprin α inhibitor probe will help define the therapeutic potential for small molecule meprin α inhibition and spur further drug discovery efforts in the area of zinc metalloproteinase inhibition.
| Original language | English |
|---|---|
| Article number | 197 |
| Pages (from-to) | 1-17 |
| Number of pages | 17 |
| Journal | Pharmaceuticals |
| Volume | 14 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2021 |
Bibliographical note
Publisher Copyright:© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Funding
This work was supported by the National Institutes of Health (AR066676 and CA249788 to D.M.). This work was also supported by the Deutsche Forschungsgemeinschaft (DFG) grant SFB877 “Proteolysis as a Regulatory Event in Pathophysiology” (project A9 and A15) (both to C.B.-P.).
ASJC Scopus Subject Areas
- Molecular Medicine
- Pharmaceutical Science
- Drug Discovery
Keywords
- Medicinal chemistry
- Meprin α
- Meprin β
- Probe development
- Zinc metalloproteinase
Disciplines
- Medical Molecular Biology
- Pharmacy and Pharmaceutical Sciences